Title: A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
Author: Naoto Saito 1), Takeshi Hatanaka 1)*, Sachi Nakano 1), Yoichi Hazama 1), Sachiko Yoshida 1), Yoko Hachisu 1), Yoshiki Tanaka 1), Teruo Yoshinaga 1), Kenji Kashiwabara 2), Norio Kubo 3), Yasuo Hosouchi 3), Hiroki Tojima 4), Satoru Kakizaki 4)5), Toshio Uraoka 4)
  1. Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital
  2. Department of Pathology, Gunma Saiseikai Maebashi Hospital
  3. Department of Surgery, Gunma Saiseikai Maebashi Hospital
  4. Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine
  5. Department of Clinical Research, National Hospital Organization Takasaki General Medical Center
*Corresponding author: Takeshi Hatanaka
Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Kamishindenmachi 564-1, Maebashi, Gunma, Japan
Zip code 371-0821 Tel +81-27-252-6011 Fax +81-27-253-0390
E-mail: hatanaka@qk9.so-net.ne.jp
Short title: Combined hepatocellular and cholangiocarcinoma treated with Atez/Bev
Keywords: immune checkpoint inhibitor, anti-programmed death ligand-1, vascular endothelial growth factor, hepatic resection, liver cancer
Disclosures: Takeshi Hatanaka received honoraria from Eisai. Other authors declare no conflicts of interest in association with this study.
Ethics statement: Written informed consent was obtained from the patient to publish this report in accordance with the journal’s patient consent policy
Manuscript: 2096
Abstract: 50 words
References: 24
Number of Tables: 1
Number of Figures: 4 Abstract
An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.